GNTA
Closed
Genenta Science Spa Adr
3.82
+0.78 (+25.62%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.045
Day's Range: 2.74 - 3.82
Send
sign up or login to leave a comment!
When Written:
5.75
Genenta Science SpA is a biotechnology company that specializes in the development of gene therapies for cancer. The company is based in Milan, Italy, and was founded in 2014. Genenta Science's lead product candidate, GEN-1, is a gene therapy that is designed to target solid tumors. The therapy works by delivering a gene that produces an immune-stimulatory protein directly to the tumor site, which can help to activate the patient's immune system to attack the cancer cells.
In 2021, Genenta Science announced that it had received approval from the US Food and Drug Administration (FDA) to begin a Phase I/II clinical trial of GEN-1 in patients with advanced ovarian cancer. The company has also received funding from various sources, including the European Union's Horizon 2020 program and the Italian Ministry of Health.
Genenta Science's American Depositary Receipts (ADRs) are traded on the Nasdaq under the ticker symbol "GNTA." ADRs are a type of security that represents ownership in a foreign company and can be traded on US stock exchanges.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
In 2021, Genenta Science announced that it had received approval from the US Food and Drug Administration (FDA) to begin a Phase I/II clinical trial of GEN-1 in patients with advanced ovarian cancer. The company has also received funding from various sources, including the European Union's Horizon 2020 program and the Italian Ministry of Health.
Genenta Science's American Depositary Receipts (ADRs) are traded on the Nasdaq under the ticker symbol "GNTA." ADRs are a type of security that represents ownership in a foreign company and can be traded on US stock exchanges.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








